IP Library Granted Patent US 11,135,175
Granted Patent B2
US 11,135,175 · App. 16/504,467 · Granted Oct 5, 2021

Active component encapsulated, protected and stabilized within a protein shell

Inventor: Sinead Doherty (Dublin, IE)
Assignee: Anabio Technologies Limited
A61K9/5052A23L33/10A23L33/105A23L33/175A23P10/30A61K9/5089A61K31/198A61K36/67
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,135,175
App. No.
16/504,467
Granted
Oct 5, 2021
Kind
B2
Abstract

A microcapsule includes an active component encapsulated within a polymerized hydrolyzed protein shell. The microcapsule has an average diameter that is less than one hundred micrometers as determined by a laser diffractometer.

Claims (24)

1. A manufacture comprising a microcapsule, wherein said microcapsule comprises an active component encapsulated within a polymerized hydrolyzed protein shell.

2. The manufacture of claim 1 , wherein said microcapsule is of average diameter as determined by a laser diffractometer, wherein said average diameter is 20 to 1000 micrometers.

3. The manufacture of claim 1 , wherein said microcapsule is of average diameter as determined by a laser diffractometer, wherein said average diameter is less than one hundred micrometers.

4. The manufacture of claim 1 , wherein the active component is selected from the group consisting of a creatine moiety, L-glutamine, L-leucine, beta-alanine, and a branched chain amino acid.

5. The manufacture of claim 1 , wherein the active component is a creatine moiety.

6. The manufacture of claim 1 , wherein the active component is selected from the group consisting of a creatine salt, a creatine complex, and a creatine derivative.

7. The manufacture of claim 1 , wherein the hydrolyzed protein comprises hydrolyzed whey protein.

8. The manufacture of claim 1 , wherein the microcapsule further comprises pepper extract.

9. The manufacture of claim 7 , wherein the pepper extract is bioperine.

10. The manufacture of claim 1 , wherein the microcapsule further comprises astaxanthin dissolved in a fatty acid.

11. The manufacture of claim 1 , wherein the microcapsule further comprises a phosphate crosslinker that crosslinks amino acids in the polymerized hydrolyzed protein chains.

12. The manufacture of claim 1 , wherein the microcapsule further comprises a phosphate crosslinker, that crosslinks amino acids in the polymerized hydrolyzed protein chains, wherein the polymerized hydrolyzed protein comprises glycerol.

13. The manufacture of claim 1 , wherein the microcapsule further comprises 10-25% hydrolyzed protein (w/v).

14. The manufacture of claim 1 , wherein the microcapsule comprises 75-90% active component (w/v).

15. The manufacture of claim 1 , wherein the microcapsule comprises 1.0-0.5% pepper extract (w/v).

16. The manufacture of claim 1 , wherein the microcapsule comprises 10-20% hydrolyzed protein (w/v), 80-90% active component (w/v), and 0.01-0.05% pepper extract (w/v).

17. The manufacture of claim 16 , wherein the microcapsule further comprises a phosphate moiety.

18. The manufacture of claim 1 , wherein said microcapsule comprises 10-20% hydrolyzed protein (w/v), 80-90% active component (w/v), and 0.01-0.05% bioperine (w/v).

19. The manufacture of claim 18 , wherein the microcapsule further comprises a substance selected from the group consisting of a phosphate moiety, 0.04-0.07% glycerol (w/v), 0.03-0.08% astaxanthin (w/v), and 0.6-0.9% alpha-lipoic acid (w/v).

20. The manufacture of claim 1 , wherein the microcapsule comprises 10-20% hydrolyzed protein (w/v), 80-90% active component (w/v), 0.01-0.05% bioperine (w/v), a phosphate moiety, 0.04-0.07% glycerol (w/v), 0.03-0.08% astaxanthin (w/v), and 0.6-0.9% alpha-lipoic acid (w/v).

21. The manufacture of claim 1 , wherein the microcapsule is stable in water for a period of at least twenty-eight days.

22. The manufacture of claim 1 , further comprising a multiplicity of additional microcapsules, wherein each of said additional microcapsules comprises an active component encapsulated within a polymerized hydrolyzed protein shell, said microcapsule having an average diameter of less than 100 micrometers as determined by a laser diffractometer.

23. The manufacture of claim 21 , wherein said manufacture is selected from the group consisting of a comestible sports nutrition product, a food, a beverage, a supplement, a powder, a particulate material, a unit dose product, and a tablet.

24. The manufacture of claim 1 , wherein the enzymatically hydrolyzed protein has a degree of hydrolysis (% DH) of 18 to 85%.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2022
From: ZANTEBIO LIMITED
To: ANABIO TECHNOLOGIES LIMITED
Reel/Frame 059540/0239 →
CHANGE OF NAME Recorded Apr 1, 2022
From: NUABIOME LIMITED
To: ZANTEBIO LIMITED
Reel/Frame 059470/0273 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 8, 2021
From: ANABIO TECHNOLOGIES LIMITED
To: NUABIOME LIMITED
Reel/Frame 057409/0412 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 8, 2019
From: DOHERTY, SINEAD
To: ANABIO TECHNOLOGIES LIMITED
Reel/Frame 049685/0376 →
Priority Claims (1)
EP 13171757 · Jun 12, 2013 · regional
Continuity (2)
Division 14897901
Related Publication 20190328676A1 · Oct 31, 2019